| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
31,804,000 |
| Market
Cap: |
845.35(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$13.85 - $26.47 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : 609 |
| Guru Rank Value : 3 |
| Guru Occurances : 1 |
|
|
|
|
|
| |
|
Company Profile AnaptysBio is a clinical stage biotechnology company developing immunology therapeutic product candidates focused on immune control mechanisms applicable to inflammation and immuno-oncology indications. Co.'s wholly-owned antibody programs include: imsidolimab, which inhibits the interleukin-36 receptor and is being developed for the treatment of multiple dermatological inflammatory diseases; rosnilimab, which is an anti-PD-1 agonist antibody program designed to augment PD-1 signaling via rosnilimab treatment to suppress T-cell driven human inflammatory diseases; and ANB032, which is applicable to human inflammatory diseases associated with lymphoid and myeloid immune cell dysregulation.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
668,237 |
| Total Buy Value |
$0 |
$0 |
$0 |
$14,453,966 |
| Total People Bought |
0 |
0 |
0 |
1 |
| Total Buy Transactions |
0 |
0 |
0 |
1 |
| Total Shares Sold |
153,940 |
171,792 |
185,897 |
858,303 |
| Total Sell Value |
$3,514,453 |
$3,902,662 |
$4,176,146 |
$18,726,680 |
| Total People Sold |
2 |
4 |
4 |
5 |
| Total Sell Transactions |
3 |
9 |
14 |
18 |
| End Date |
2024-02-04 |
2023-11-03 |
2023-05-05 |
2022-05-05 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Loumeau Eric J |
COO, General Counsel |
• – – |
2022-06-08 |
4 |
OE |
$14.02 |
$35,050 |
D/D |
2,500 |
3,023 |
|
- |
|
| Loumeau Eric J |
COO, General Counsel |
• – – |
2022-05-18 |
4 |
AS |
$20.50 |
$23,493 |
D/D |
(1,146) |
523 |
|
29% |
|
| Nodelman Oleg |
Director |
– • • |
2022-05-05 |
4 |
S |
$21.63 |
$14,453,966 |
I/I |
(668,237) |
7,521,024 |
|
-18% |
|
| Nodelman Oleg |
Director |
– • • |
2022-05-05 |
4 |
B |
$21.63 |
$14,453,966 |
I/I |
668,237 |
7,521,024 |
2.25 |
18% |
|
| Faga Daniel |
Interim CEO |
• • – |
2022-03-21 |
4 |
A |
$0.00 |
$0 |
D/D |
887,043 |
887,043 |
|
- |
|
| Suria Hamza |
President, CEO |
• • – |
2021-12-20 |
4 |
AS |
$34.89 |
$1,303,559 |
D/D |
(36,645) |
68,600 |
|
-33% |
|
| Suria Hamza |
President, CEO |
• • – |
2021-12-20 |
4 |
OE |
$1.12 |
$41,042 |
D/D |
36,645 |
105,245 |
|
- |
|
| Suria Hamza |
President, CEO |
• • – |
2021-11-15 |
4 |
A |
$22.03 |
$21,237 |
D/D |
964 |
68,600 |
|
- |
|
| Lizzul Paul F. |
Chief Medical Officer |
• – – |
2021-11-15 |
4 |
A |
$22.03 |
$21,237 |
D/D |
964 |
964 |
|
- |
|
| Loumeau Eric J |
COO, General Counsel |
• – – |
2021-11-15 |
4 |
A |
$22.03 |
$11,522 |
D/D |
523 |
523 |
|
- |
|
| Mulroy Dennis |
Chief Financial Officer |
• – – |
2021-11-15 |
4 |
A |
$22.03 |
$21,237 |
D/D |
964 |
964 |
|
- |
|
| Suria Hamza |
President, CEO |
• • – |
2021-11-05 |
4 |
AS |
$35.00 |
$500,570 |
D/D |
(14,302) |
67,636 |
|
-28% |
|
| Suria Hamza |
President, CEO |
• • – |
2021-11-05 |
4 |
OE |
$1.12 |
$16,018 |
D/D |
14,302 |
81,938 |
|
- |
|
| Suria Hamza |
President, CEO |
• • – |
2021-11-04 |
4 |
AS |
$35.00 |
$212,065 |
D/D |
(6,059) |
67,636 |
|
-20% |
|
| Suria Hamza |
President, CEO |
• • – |
2021-11-04 |
4 |
OE |
$1.12 |
$6,786 |
D/D |
6,059 |
73,695 |
|
- |
|
| Loumeau Eric J |
COO, General Counsel |
• – – |
2021-11-04 |
4 |
AS |
$35.00 |
$175,000 |
D/D |
(5,000) |
0 |
|
-20% |
|
| Loumeau Eric J |
COO, General Counsel |
• – – |
2021-11-04 |
4 |
OE |
$14.02 |
$85,450 |
D/D |
5,000 |
5,000 |
|
- |
|
| Suria Hamza |
President, CEO |
• • – |
2021-11-01 |
4 |
AS |
$32.27 |
$1,184,106 |
D/D |
(36,646) |
67,636 |
|
-17% |
|
| Suria Hamza |
President, CEO |
• • – |
2021-11-01 |
4 |
OE |
$1.12 |
$41,044 |
D/D |
36,646 |
104,282 |
|
- |
|
| Suria Hamza |
President, CEO |
• • – |
2021-10-26 |
4 |
AS |
$30.00 |
$479,790 |
D/D |
(15,993) |
67,636 |
|
-0% |
|
| Suria Hamza |
President, CEO |
• • – |
2021-10-26 |
4 |
OE |
$1.12 |
$17,912 |
D/D |
15,993 |
83,629 |
|
- |
|
| Suria Hamza |
President, CEO |
• • – |
2021-09-17 |
4 |
OE |
$1.12 |
$11,200 |
D/D |
10,000 |
67,636 |
|
- |
|
| Suria Hamza |
President, CEO |
• • – |
2021-05-12 |
4 |
OE |
$1.12 |
$11,200 |
D/D |
10,000 |
57,636 |
|
- |
|
| Nodelman Oleg |
Director |
– • • |
2021-05-04 |
4 |
B |
$23.25 |
$3,835,755 |
I/I |
165,000 |
7,520,424 |
2.25 |
11% |
|
| Nodelman Oleg |
Director |
– • • |
2021-05-03 |
4 |
B |
$23.31 |
$484,873 |
I/I |
20,800 |
7,355,424 |
2.25 |
9% |
|
130 Records found
|
|
Page 2 of 6 |
|
|
0.24 (0.91%) 
